The NeurologyLive® movement disorders clinical focus page is a source for all the latest news regarding the clinical care of patients with Parkinson disease, essential tremor, Huntington disease, dystonia, ataxia, and more. This page features podcasts, videos, and news about FDA actions, study and clinical trial findings, clinical guideline updates, and interviews with experts in the clinical care of movement disorders.
October 28th 2024
As part of our monthly clinician spotlight, NeurologyLive® highlighted movement disorder expert Sana Aslam, DO, an assistant professor of neurology at University of Colorado School of Medicine.
Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis - Current Treatment and Emerging Con...
November 12, 2024
Register Now!
Recognizing Rett Syndrome Early to Improve Long-term Management Outcomes
View More
2024 Neuromuscular Summit
November 20, 2024
View More
5th Annual International Congress on the Future of Neurology®
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Advances In™ Generalized Myasthenia Gravis: Improving Patient Outcomes Through Early Diagnosis and Management
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
Burst CME: Optimizing Therapy in Parkinson’s Disease
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Community Practice Connections™: Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors
View More
Burst Expert Illustrations & Commentary™ : Visualizing the Role of the Complement Proteins in Neurologic Disorders
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Burst Expert Illustrations & Commentary™: Visualizing the Implications of Anti-Complement Therapies on Generalized Myasthenia Gravis
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of the Complement Pathway in Neurological Disorders
View More
Individualizing Treatment for Patients with Generalized Myasthenia Gravis
View More
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Clinical ShowCase™ in ALS: Addressing Diagnostic Delays, Evolving Therapies, and Multidisciplinary Care
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of FcRN in Neurological Disorders
View More
BURST Expert Illustrations and Commentaries™: Visualizing FcRn as a Therapeutic Target in Neurological Disease
View More
BURST Expert Illustrations and Commentaries™: Visualizing the Implications of FcRN-Targeted Therapies on Generalized Myasthenia Gravis
View More
Clinical Consultations™: Navigating the Evolving Treatment Landscape in Generalized Myasthenia Gravis
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of Subcutaneous Infusion as an Alternate Administration Route for Medical Interventions
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy (French)
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy (Spanish)
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy (German)
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy (Italian)
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
BURST CME™ Part I: Understanding the Impact of Huntington’s Disease
View More
The AI Revolution That Could Slow Parkinson In Its Tracks
April 19th 2024Neal K. Shah, CEO of CareYaya Health Technologies, an AI innovator in neurological care, discussed how technology is poised to transform the fight against Parkinson, with the potential to improve millions of lives and advance health equity.
Pridopidine Maintains Effectiveness in Huntington Disease Without Antidopaminergic Medications
April 14th 2024New findings from the phase 3 PROOF-HD trial showed that pridopidine outperformed placebo up to 78 weeks in patients with Huntington disease even after excluding those on neuroleptics and antichorea medications.
Paradigm Shift In Parkinson’s Disease Diagnosis
April 1st 2024The neurology experts discuss the importance of early and accurate diagnosis of Parkinson’s disease, the role of alpha-synuclein in the diagnosis of synucleinopathies and approaches to implementing screening protocols in clinical practice.
AC Immune SA Shares Phase 2 VacSYn Trial Update for ACI-7104.056 in Parkinson Disease
Published: March 28th 2024 | Updated: May 23rd 2024At AD/PD 2024, AC Immune SA presented an update on the company's phase 2 VacSYn trial assessing ACI-7104.056, an anti-α-synuclein active immunotherapy, for patients with Parkinson disease.